Savara Inc Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
Savara Inc (SVRA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of $71.98 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-19.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2013-03-19
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2012-12-31 was -$139.01K.
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2012-09-30 was $321.50K.
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2012 was $71.98K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$139.01K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-19 | $182.49K derived: sum of 2 quarters · filed 2013-03-19 | $71.98K 10-K · filed 2013-03-19 | |
| 2012-09-30 | $321.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $210.99K 10-Q · filed 2012-11-05 | ||
| 2012-06-30 | -$110.51K 10-Q · filed 2012-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |